๐ŸŒ EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

๐Ÿงช

Trial Match

Clinical trials test new treatments โ€” sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

๐ŸŽฏ Match trials to me

30 recruiting trials

for Unresectable Non-small Cell Lung Cancer

Study of Antitumor Immune Response After cCRT and IO Treatment in Non-resectable III Stage NSCLC Patients NCT06634199n/a22 sites๐Ÿ“ Ferrol๐Ÿ“ Alicante๐Ÿ“ Badalona Fundaciรณn GECP ยท Tests: Durvalumab Magnesium Supplementation in Advanced Non-small Cell Lung Cancer (NSCLC) NCT07149649Phase 2, Phase 311 sites๐Ÿ“ Aarau๐Ÿ“ Aarau๐Ÿ“ Baden Swiss Cancer Institute ยท Tests: Magnesiocard, Magnesium Diasporal, Microcrystalline cellulose, Isotonic saline solution 0.9% Adjuvant Chemotherapy +/- Cemiplimab and Sequential Hypofractionated Radiotherapy in Unfit or Elderly Patients With Stage III Lung Cancer NCT06656598Phase 225 sites๐Ÿ“ Angers๐Ÿ“ Angers๐Ÿ“ Avignon Intergroupe Francophone de Cancerologie Thoracique ยท Tests: Carboplatin, Paclitaxel, Cemiplimab, Curative hypofractionated radiotherapy, Cemiplimab (maintenance) A Phase I Dose Escalation and Dose Expansion Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Durvalumab NCT07391670Phase 119 sites๐Ÿ“ Fitzroy๐Ÿ“ St Albans๐Ÿ“ Woolloongabba AstraZeneca ยท Tests: SC durvalumab + rHu, IV durvalumab, Tremelimumab Risk-adapted, Proteomic-guided Systemic Therapy for Previously Untreated Advanced Non-small Cell Lung Cancer NCT07250477Phase 24 sites๐Ÿ“ Chico๐Ÿ“ Marysville๐Ÿ“ Sacramento University of California, Davis ยท Tests: Systemic (ICI)-based therapy informed by the PROphet CB assay and the CARG-TT assessment., Standard of Care Neoadjuvant IBI308, Bevacizumab, Plus Pemetrexed and Carboplatin Followed by Surgery in Unresectable Stage III NSCLC NCT03872661Phase 21 site๐Ÿ“ Guangzhou Sun Yat-sen University ยท Tests: IBI308, Bevacizumab, Pemetrexed, Carboplatin, Thoracic surgery A Phase III Study to Assess the Effects of Almonertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer NCT04951635Phase 31 site๐Ÿ“ Ji'nan Jiangsu Hansoh Pharmaceutical Co., Ltd. ยท Tests: Almonertinib, Placebo Almonertinib PACCELIO - FDG-PET Based Small Volume Accelerated Immuno Chemoradiotherapy in Locally Advanced NSCLC NCT06102057Phase 211 sites๐Ÿ“ Dresden๐Ÿ“ Essen๐Ÿ“ Freiburg im Breisgau TheraOp ยท Tests: standard Radiotherapy, Chemotherapy, Immunotherapy, Experimental Radiotherapy Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer NCT06890598Phase 3366 sites๐Ÿ“ Huntsville๐Ÿ“ Mobile๐Ÿ“ Phoenix Eli Lilly and Company ยท Tests: Olomorasib, Pembrolizumab, Durvalumab, Placebo A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors NCT07488676Phase 1, Phase 221 sites๐Ÿ“ Birmingham๐Ÿ“ Los Angeles๐Ÿ“ Miami Astellas Pharma Global Development, Inc. ยท Tests: ASP546C A Study of BL-M07D1 in Combination With Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic HER2-Overexpressing Non-Squamous NSCLC NCT07264816Phase 21 site๐Ÿ“ Wuhan Sichuan Baili Pharmaceutical Co., Ltd. ยท Tests: BL-M07D1, Pembrolizumab Induction Chemoimmunotherapy in Combination With Chemoradiotherapy and Consolidation Immunotherapy in Unresectable Locally Advanced Non-Small Cell Lung Cancer NCT07632365Phase 1, Phase 21 site๐Ÿ“ Shanghai Shanghai Chest Hospital ยท Tests: Induction chemoimmunotherapy, Concurrent chemoradiotherapy (cCRT), consolidation immunotherapy A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors NCT07094204Phase 120 sites๐Ÿ“ Santa Monica๐Ÿ“ Atlanta๐Ÿ“ Jefferson Astellas Pharma Inc ยท Tests: ASP5834, panitumumab Targeted Induction Therapy for Stage III Unresectable EGFR Mutant Positive NSCLC NCT07742332Phase 21 site๐Ÿ“ Shanghai Peng Zhang ยท Tests: Fumetinib combined platinum-based double chemotherapy, Concurrent Radiochemotherapy A Phase 2 Clinical Study of ABSK061 and ABSK043 NCT06632262Phase 221 sites๐Ÿ“ Guiyang๐Ÿ“ Guiyang๐Ÿ“ Shijiazhuang Abbisko Therapeutics Co, Ltd ยท Tests: ABSK061 + ABSK043, ABSK061+ABSK043 in combination with CAPOX A Study Comparing BL-B01D1 in Combination With Osimertinib Versus Osimertinib Alone in Patients With Locally Advanced, Unresectable EGFR-mutated Non-small Cell Lung Cancer(Stage III) Whose Disease Has Not Progressed Following Definitive Platinum-based Chemoradiation Therapy(PANKU-Lung08) NCT07640789Phase 31 site๐Ÿ“ Jinan Sichuan Baili Pharmaceutical Co., Ltd. ยท Tests: BL-B01D1, Osimertinib A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations NCT06835569Phase 114 sites๐Ÿ“ Orlando๐Ÿ“ Tampa๐Ÿ“ Boston Alterome Therapeutics, Inc. ยท Tests: ALTA3263, cetuximab, mFOLFOX6, Pembrolizumab, Pemetrexed + Cisplatin /Carboplatin Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer NCT06899126Phase 3246 sites๐Ÿ“ Anchorage๐Ÿ“ Fountain Valley๐Ÿ“ Los Angeles Daiichi Sankyo ยท Tests: Trastuzumab Deruxtecan, pembrolizumab, Pemetrexed, Platinum Chemotherapy A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors NCT05592626Phase 1, Phase 219 sites๐Ÿ“ Sacramento๐Ÿ“ Celebration๐Ÿ“ Miami Marengo Therapeutics, Inc. ยท Tests: STAR0602, Irinotecan (Camptosar), Docetaxel (Taxotere) PALACE: Cemiplimab Trial According to ctDNA Levels NCT06917573Phase 220 sites๐Ÿ“ Alicante๐Ÿ“ Elche๐Ÿ“ Badalona Fundaciรณn GECP ยท Tests: Cemiplimab, Carboplatin, Paclitaxel Chemoradiotherapy With Surgery Followed by Consolidation Durvalumab NCT06908070Phase 41 site๐Ÿ“ Amsterdam Idris Bahce ยท Tests: Consolidation durvalumab A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) NCT07154290Phase 218 sites๐Ÿ“ Birmingham๐Ÿ“ Goodyear๐Ÿ“ Irvine Regeneron Pharmaceuticals ยท Tests: Ubamatamab, Marlotamig, Sarilumab A Study of NX-1607 in Adults With Advanced Malignancies NCT05107674Phase 117 sites๐Ÿ“ Duarte๐Ÿ“ Los Angeles๐Ÿ“ San Francisco Nurix Therapeutics, Inc. ยท Tests: NX-1607, Paclitaxel IBI363 (PD-1/IL-2ฮฑ-bias) in Combination With Chemotherapy as Neoadjuvant Therapy in Initially Unresectable Stage III Non-Small Cell Lung Cancer NCT07408635Phase 21 site๐Ÿ“ Shanghai Shanghai Pulmonary Hospital, Shanghai, China ยท Tests: IBI363 + Chemotherapy A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors NCT06244771Phase 1, Phase 226 sites๐Ÿ“ La Jolla๐Ÿ“ Orange๐Ÿ“ San Francisco Frontier Medicines Corporation ยท Tests: FMC-376 Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer NCT05098210Phase 11 site๐Ÿ“ Seattle Fred Hutchinson Cancer Center ยท Tests: Neoantigen Peptide Vaccine, Nivolumab, Poly ICLC, Echocardiography Test, Multigated Acquisition Scan Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rฮฑ Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer NCT05267626Phase 1, Phase 217 sites๐Ÿ“ Miami๐Ÿ“ Grand Rapids๐Ÿ“ Minneapolis Aulos Bioscience, Inc. ยท Tests: AU-007, Aldesleukin, Avelumab, Nivolumab Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors NCT05983432Phase 137 sites๐Ÿ“ Beverly Hills๐Ÿ“ Duarte๐Ÿ“ Orange SystImmune Inc. ยท Tests: BL-B01D1 RGL-270 + ICI in Advanced NSCLC NCT07652125NA1 site๐Ÿ“ Guangzhou Guangdong Association of Clinical Trials ยท Tests: RGL-270 in Combination with PD-1/PD-L1 Inhibitors, Physician's Choice SOC A Study of AK104 in Subjects With Unresectable Locally Advanced NSCLC NCT06617416Phase 31 site๐Ÿ“ Jinan Akeso ยท Tests: Cadonilimab (AK104), Sugemalimab
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy